ArticleAdvanced materials (Deerfield Beach, Fla.)2026
Leveraging Mitochondria-Endoplasmic Reticulum Functional Interplay With an On-Demand Nanoparticle to Boost mtDNA-Based STING Immunotherapy.
Article in Advanced materials (Deerfield Beach, Fla.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Endogenous STING activation by mitochondrial DNA (mtDNA) offers a tumor-context-dependent strategy with potentially reduced off-target toxicity, but is often limited by weak and transient mtDNA-driven STING signaling that fails to sustain robust STING clustering. Here, we developed an on-demand nanoparticle system that harnesses mitochondrial-ER functional interplay by concurrently inducing mtDNA release and ER stress, thereby relieving the STIM1-mediated brake on STING and enabling robust STING-TBK1 assembly and downstream signaling. This strategy markedly increased the phosphorylation levels of STING, TBK1, and IRF3 by 11.50-, 9.70-, and 8.95-fold, respectively, compared with PBS, outperforming the commercial STING agonist MSA-2 by more than 2-fold. In addition, the nanoparticles enabled spatially controlled co-delivery, allowing extracellular release of a PD-1/PD-L1 inhibitor and intracellular release of mtDNA-releasing and ER stress-inducing agents. Consequently, this on-demand nanoparticle system potently enhanced both innate and adaptive antitumor immunity in vivo, significantly increasing CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.